News | May 22, 2024
AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030
Launch of 20 new medicines expected by 2030
Launch of 20 new medicines expected by 2030
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
The collaboration aims to bolster healthcare entrepreneurship
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Subscribe To Our Newsletter & Stay Updated
